Adults

One tablet once daily, preferably with a meal.

Elderly

No dosage adjustment typically required, but caution due to increased risk of side effects and impaired renal function. Start with lowest effective dose.

Renal_impairment

Contraindicated in severe renal impairment (CrCl < 30 mL/min). For mild to moderate renal impairment, dose adjustment or careful monitoring may be necessary. Rosuvastatin component requires caution with CrCl < 60 mL/min.

Onset

Lipid-lowering effects of Rosuvastatin are usually seen within 1 week, with maximum effect by 2-4 weeks. Fenofibrate's maximum effects on lipids are generally achieved within 2 weeks.

Excretion

Rosuvastatin: Primarily excreted unchanged in feces (90%). Fenofibric acid: Primarily excreted in urine as fenofibric acid and fenofibric acid glucuronide.

Half life

Rosuvastatin: Approximately 19 hours. Fenofibric acid (active metabolite of Fenofibrate): Approximately 20 hours.

Absorption

Rosuvastatin: Absolute bioavailability is approximately 20%. Fenofibrate: Well absorbed from the gastrointestinal tract, especially when taken with food; converted to active fenofibric acid.

Metabolism

Rosuvastatin: Limited metabolism, primarily by CYP2C9 and CYP2C19. Fenofibrate: Rapidly hydrolyzed to the active metabolite fenofibric acid, which is glucuronidated and then excreted.

Colchicine

Increased risk of myopathy/rhabdomyolysis.

Gemfibrozil

Increased risk of myopathy/rhabdomyolysis, avoid co-administration with Fenofibrate.

Cyclosporine

Increased Rosuvastatin exposure, avoid co-administration.

Other fibrates

Avoid combination due to increased risk of muscle toxicity.

Anticoagulants (e.g., Warfarin)

Potentiation of anticoagulant effect, increased risk of bleeding. Close monitoring of INR is required.

CYP3A4 inhibitors (e.g., Itraconazole, Ketoconazole)

May increase statin levels, use with caution.